Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Jerome F. Cros

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4935-3865; OpenAlex author ID A5060346666. Sources: OpenAlex.

Their work

Papers
70 (first author 5, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
209
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 5 papers · 2016: 2 papers · 2017: 1 paper · 2018: 4 papers · 2019: 6 papers · 2020: 8 papers · 2021: 10 papers · 2022: 6 papers · 2023: 6 papers · 2024: 5 papers · 2025: 7 papers · 2026: 8 papers

Papers 50 of 70

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10436-4↗
  3. ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression. Co-author DOI 10.1038/s43018-026-01265-5↗
  4. Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG … Co-author DOI 10.1097/sla.0000000000006449↗
  5. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  6. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  7. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  8. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  9. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  10. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Last author DOI 10.1002/path.6398↗
  11. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  12. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  13. Distal pancreatectomy with celiac axis resection (DP-CAR) for pancreatic ductal adenocarcinoma in a retrospective monocentric cohort: neoadjuvant treatment and… Co-author DOI 10.1016/j.hpb.2025.04.009↗
  14. Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer Co-author DOI 10.1101/2025.07.07.663493↗
  15. Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1177/17588359251403909↗
  16. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  17. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  18. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  19. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Last author DOI 10.1200/jco.22.02668↗
  20. Distal Pancreatectomy for Body Pancreatic Ductal Adenocarcinoma: Is Splenectomy Necessary? A Propensity Score Matched Study. Co-author DOI 10.1245/s10434-024-15220-0↗
  21. Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. First author DOI 10.1016/j.clinre.2023.102108↗
  22. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  23. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. Co-author DOI 10.1016/s2468-1253(23)00207-8↗
  24. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Last author DOI 10.1038/s41467-023-39026-y↗
  25. Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221146132↗
  26. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
  27. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… Co-author DOI 10.1002/path.6011↗
  28. BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2022.101880↗
  29. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  30. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Last author DOI 10.1101/2022.01.04.474951↗
  31. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen-Letter. Co-author DOI 10.1158/1078-0432.ccr-21-2257↗
  32. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Co-author DOI 10.1177/17588359221118019↗
  33. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  34. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. Co-author DOI 10.1016/j.ebiom.2021.103541↗
  35. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. First author DOI 10.1016/j.ejca.2021.01.042↗
  36. Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. Co-author DOI 10.1016/j.ejca.2021.06.038↗
  37. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
  38. Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. Co-author DOI 10.1158/1078-0432.ccr-21-1907↗
  39. Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential dia… Co-author DOI 10.1177/17588359211053412↗
  40. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Last author DOI 10.3390/cancers13061234↗
  41. Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13122986↗
  42. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcom… Co-author DOI 10.3390/ijms22136756↗
  43. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102858↗
  44. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Co-author DOI 10.1016/j.ejca.2019.10.020↗
  45. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Co-author DOI 10.1016/j.ejca.2020.02.004↗
  46. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  47. PARP inhibition in treatment of pancreatic cancer. Co-author DOI 10.1080/14737140.2020.1820330↗
  48. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-0950↗
  49. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. Co-author DOI 10.15252/emmm.202012010↗
  50. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers12113204↗

Closest collaborators

The 25 strongest of 209 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rémy Nicolle · 27 shared papers, 2019–2026 · strength 4.02
  2. Jean‐Baptiste Bachet · 32 shared papers, 2013–2026 · strength 3.98
  3. Pascal R. Hammel · 31 shared papers, 2013–2026 · strength 3.62
  4. Louis de Mestier · 18 shared papers, 2015–2026 · strength 2.57
  5. Vinciane Rebours · 16 shared papers, 2016–2026 · strength 2.27
  6. Nelson Dusetti · 15 shared papers, 2019–2026 · strength 2.20
  7. Cindy Neuzillet · 17 shared papers, 2013–2026 · strength 2.09
  8. Juan Iovanna · 14 shared papers, 2017–2026 · strength 1.91
  9. Magali Svrcek · 17 shared papers, 2013–2024 · strength 1.70
  10. Anthony Turpin · 8 shared papers, 2022–2026 · strength 1.47
  11. Thierry Conroy · 7 shared papers, 2024–2026 · strength 1.43
  12. Aurélien Lambert · 6 shared papers, 2024–2026 · strength 1.24
  13. James Biagi · 6 shared papers, 2024–2026 · strength 1.23
  14. Anne Couvelard · 10 shared papers, 2015–2025 · strength 1.11
  15. Jérôme Raffenne · 8 shared papers, 2018–2025 · strength 1.00
  16. Alain Sauvanet · 9 shared papers, 2013–2025 · strength 0.99
  17. Safi Dokmak · 5 shared papers, 2019–2025 · strength 0.88
  18. Marc Hilmi · 5 shared papers, 2021–2026 · strength 0.87
  19. Alexandre Harlé · 4 shared papers, 2024–2026 · strength 0.83
  20. Pierre Laurent‐Puig · 6 shared papers, 2019–2026 · strength 0.81
  21. Olivier Bouché · 5 shared papers, 2020–2026 · strength 0.76
  22. Daniel John Renouf · 4 shared papers, 2024–2026 · strength 0.74
  23. Valérie Paradis · 8 shared papers, 2015–2023 · strength 0.72
  24. Jean‐Luc Van Laethem · 7 shared papers, 2013–2023 · strength 0.65
  25. Shulin Zhao · 4 shared papers, 2021–2026 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.